MaaT Pharma focuses on the discovery and development of Microbiome Ecosystem Therapies™ that leverage consortia of gut bacteria to address serious diseases. Its lead asset, Xervyteg®, is being readied for commercialization in Europe with a launch target in the second half of 2026, while preparations are underway for U.S. pivotal studies slated to begin in early 2026 following FDA discussions. The company is also advancing the MaaT033 clinical trial in Europe. To support these programs, MaaT Pharma reported cash and cash equivalents of €22.4 million as of 30 September 2025, a figure that includes a €10.5 million upfront payment from a commercial partner. Management believes current resources will fund operations through February 2026, with the potential to draw a second tranche of European Investment Bank financing that could extend the runway to August 2026. The firm continues to evaluate additional financing options to further bolster its cash position.

Total raised

$104M

Funding rounds

7

Latest round

Equity

Latest activity

Nov 2025